Sandoz | Sustainability Performance
Develops and supplies generic pharmaceuticals and biosimilar medicines.
1886
Switzerland
10,001+ employees
Pharmaceuticals
$10B+ in revenue
$500M - 1B in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#3189
Overallⓘ#100
in Switzerlandⓘ#77
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsEnergy consumptionWaste ManagementWater ManagementNature and biodiversitySocial
Diversity and InclusionExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Laggard
Laggard
Aligned
Critical
Intensity
Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)
Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)
Energy consumption (direct) intensity (MWh /$M)
Water consumption intensity (m³ /$M)
Waste generation intensity (tonnes /$M)
Industry Benchmark
17.6
B/M 13.9
198.0
B/M 111.2
74.7
B/M 65.5
35.9
B/M 121.5
4.8
B/M 1.1
Powered by illuminem and GIST Impact
Controversy level
- Sandoz's Novartis spin-off created standalone financial and operational challenges.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
11+
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.